Journals / Turkish Thoracic Journal / 2020 / Cilt: 21 - Sayı: 4

Managing Bronchiectasis: 13 Years of Experience from Sputum to Lung Transplantation

Pages
261–265
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Sputum culture results were available in 365 (52.6%)of the patients.Pseudomonas aeruginosa was the leading pathogen, which was found in 68 (20.7%) patients.28 (4%) patients have died during the 13 year period, and the overall survival was 125,3 months.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVES: Bronchiectasis and especially related mortality has gained growing interest in recent years.The aim of our retrospective study was to determine the factors which may influence and indicate mortality in our bronchiectasis patients throughout 13 years.MATERIAL AND METHODS: Patients with ICD-10 code J47 depicting bronchiectasis between 1.1.2003 to 31.12.2015 were evaluated using database of our hospital.694 out of 1470 patients who had high-resolution computed tomography (HRCT) scan confirming the presence of bronchiectatic lesions were included.RESULTS: Female/male ratio was 1.09.
📊
Key Findings & Data:Mean age of the patients was 45.9±15.7 years.
💡
Conclusion & Impact:Sputum culture results were available in 365 (52.6%)of the patients.Pseudomonas aeruginosa was the leading pathogen, which was found in 68 (20.7%) patients.28 (4%) patients have died during the 13 year period, and the overall survival was 125,3 months.
🔬Design:Research Article
📍Scope:2003 Verileri
⚙️Variables:Domain Parameters

Abstract

OBJECTIVES: Bronchiectasis and especially related mortality has gained growing interest in recent years.The aim of our retrospective study was to determine the factors which may influence and indicate mortality in our bronchiectasis patients throughout 13 years.MATERIAL AND METHODS: Patients with ICD-10 code J47 depicting bronchiectasis between 1.1.2003 to 31.12.2015 were evaluated using database of our hospital.694 out of 1470 patients who had high-resolution computed tomography (HRCT) scan confirming the presence of bronchiectatic lesions were included.RESULTS: Female/male ratio was 1.09. Mean age of the patients was 45.9±15.7 years. Sputum culture results were available in 365 (52.6%)of the patients.Pseudomonas aeruginosa was the leading pathogen, which was found in 68 (20.7%) patients.28 (4%) patients have died during the 13 year period, and the overall survival was 125,3 months. In general 5 (4.4%) out of 112 patients who underwent surgery were lost, 3 of them belonging to the transplantation group. 3 out of 9 patients (33%) who underwent lung transplantation were lost within 3 years.There was no statistically significant difference in survival between patients who underwent surgery or not (p>0.05).In univariate Cox regression mortality analysis age, FEV1, P. aeruginosa, E.coli, hospitalisation and ICU admission had p value

🔖

Cite This Article

UZEL, F. I., UZEL, B., KUTLUK, A. C., ALTIN, S., YENTÜRK, E., TUNCAY, E. (2022). Managing Bronchiectasis: 13 Years of Experience from Sputum to Lung Transplantation. Turkish Thoracic Journal, Cilt: 21 - Sayı: 4, 261–265. https://ajindex.com/articles/618102

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Polverino E, Goeminne PC, McDonell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017;50:1700629. DOI: 10.1183/13993003.00629-2017. [CrossRef] 2. Ellis HC, Steven Cowman S, Fernandes M, et al. Predicting mortality in bronchiectasis using bronchiectasis severity index and FACED scores: A 19-year cohort study. Eur Respir J 2016;47:482- 9. [CrossRef] 3. Goeminne PC, Nawrot TS, Ruttens D, et al. Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. Respir Med 2014;108:287-96. [CrossRef] 4. Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009;34:843-9. [CrossRef] 5. Onen ZP, Gulbay BE, Sen E, et al. Analysis of the factors related to mortality in patients with bronchiectasis. Respir Med 2007;101:1390-7. [CrossRef] 6. Finch S, McDonnell MJ, Abo-Leyah H, et al. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann Am Thorac Soc 2015;12:1602-11. [CrossRef] 7. Wang H, Ji X-B, Mao B, et al. Pseudomonas aeruginosa isolation in patients with noncystic fibrosis bronchiectasis: A retrospective study. BMJ Open 2018;8:e014613. doi: 10.1136/bmjopen- 2016-014613. [CrossRef] 8. Fan LC, Liang S, Lu H-W, et al. Efficiency and safety of surgical intervention to patients with Non-Cystic Fibrosis bronchiectasis: A meta-analysis. Sci Rep 2015;5:17382. doi: 10.1038/ srep17382. [CrossRef] 9. Pasteur MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65Suppl 1:i1-58. [CrossRef] 10. Chalmers JD, Goeminne P, Aliberti S, et al. The Bronchiectasis Severity Index: An international derivation and validation study. Am J Respir Crit Care Med 2014;189:576-85. [CrossRef] 11. Aliberti S, Masefield S, Polverino E, et al. Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration. Eur Respir J 2016;48:632-47. [CrossRef] 12. Rademacher J, Ringshausen FC, Suhling H, et al. Lung transplantation for non-cystic fibrosis bronchiectasis. Respir Med 2016;115:60-5. [CrossRef]